Actively Recruiting
CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research
Led by Clinical Hub for Interventional Research (CHOIR) · Updated on 2026-05-13
100
Participants Needed
1
Research Sites
397 weeks
Total Duration
On this page
Sponsors
C
Clinical Hub for Interventional Research (CHOIR)
Lead Sponsor
M
Medical Research Future Fund
Collaborating Sponsor
AI-Summary
What this Trial Is About
People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study. Individuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH. Researchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes. The information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia. Participants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.
CONDITIONS
Official Title
CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 55 years and above
- Confirmed clonal haematopoiesis (CH) or possible CH defined by persistent, non-severe low blood counts on at least 2 occasions 4 months apart
- Persistent low neutrophil count below 1.8 x 10^9/L, or hemoglobin below 120 g/L (females) or 130 g/L (males), or platelet count below 150 x 10^9/L
- Ability to provide written informed consent before any study procedures
You will not qualify if you...
- Severe low blood cell counts defined as neutrophils below 0.5 x 10^9/L, hemoglobin below 80 g/L, or platelets below 50 x 10^9/L
- Presence of marked trilineage cytopenia with neutrophils below 1.0 x 10^9/L, hemoglobin below 110 g/L, and platelets below 100 x 10^9/L
- Presence of marked bilineage cytopenia with two or more of the following: neutrophils below 1.0 x 10^9/L, hemoglobin below 110 g/L, or platelets below 100 x 10^9/L
- Individuals with possible CH and these severe cytopenias will be excluded from the CH clinic and referred for urgent evaluation unless no cause is found and the study PI agrees
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Canberra Health Services
Canberra, Australian Capital Territory, Australia, 2605
Actively Recruiting
Research Team
M
Mark Polizzotto Professor
CONTACT
J
Jun Yen Ng Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here